) in C57BL/6 mice using either cationic liposomes showed the ability of nonsyngeneic MHC antigens to or retroviral vectors as mediators. 7 In both cases, the Henhance immunogenicity of tumor cells. 1 With the avail-2K s -treated animals demonstrated attenuated tumor ability of molecular biological tools, we and others have growth and, with optimization of the system, increased exploited the introduction of allogeneic MHC genes [2] [3] [4] [5] [6] [7] survival and some complete responses. 7 It was also sugand 'foreign' genes 8 to generate tumor-specific immunity. gested that the mechanism of activity was through speThe introduction of allogeneic MHC and 'foreign' DNA cific T cell recognition. 7 With this background, Nabel et into tumors leads to the subsequent rejection of tumors al 10 developed a phase I program for liposome-DNAin vivo and the generation of tumor-specific CTL against mediated HLA-B7 transduction of malignant melanoma the 'wild-type', parental tumor. [2] [3] [4] [5] [6] [7] [8] [9] Therefore, the introthrough direct injection of HLA-B7-liposome complexes duction of the H-2K b gene, an allogeneic MHC class I into patients. These results are confined to the expression gene, into the AKR mouse leukemia cell line K36 generof the HLA-B7 gene in non-HLA-B7 melanoma patients. 10 ated a strong tumor-specific immunity against the 'wildBased on our own experimental studies and those of type' K36 tumor cells. 2 In this model, not only were the others, [2] [3] [4] [5] [6] [7] [8] [9] [10] we submitted and received approval from the recipient mice immune to a subsequent re-challenge with Singapore Ministry of Health and the ethics committee the parental K36 tumor cells, it also led to the regression of the Singapore General Hospital to conduct a human of established parental tumors in the AKR mice. 2 This clinical protocol to compare efficiency in the generation regression has been demonstrated to be mediated by of tumor-specific immunity employing the human HLA-CD3 + as well as CD3 − T cells. 9 Similar results have also A locus, HLA-A2 gene; the human HLA-B locus, HLAbeen reported by Plautz et al. 7 In their system, the H-2K s B13 gene and the murine H-2K k gene; into various human cancers including breast carcinoma, lung carcinoma, melanoma, cervical and ovarian carcinoma via succumbed to their disease, the procedures were well tol-DC-Chol/DOPE liposomes responded (Table 1) . The injected lesion of one patient with NSCLC regressed comerated. Moreover, it was also observed that strong local responses could be generated in the nodules treated. Of pletely while a patient with cervical carcinoma gave a partial local response (PLR) ( Table 1 ). The response the nine patients who were recruited for the toxicity study, complete tumor regression of the treated nodule observed in one of the treated patients who gave a PLR following treatment with 80 g of pHLA-A2-DCwas observed in one non-small cell lung carcinoma (NSCLC) patient while a partial regression was obtained Chol/DOPE cationic liposomes is shown in Figure 1 . For this particular patient, the response was considered a for a cervical carcinoma patient. Subsequently, 10 women with terminal cancer of the ovary and cervical cancer PLR as the treated lesion did not disappear. However, it can be seen that the shrinkage in size of the injected were similarly studied in an independent phase I/II clinical study. Of these, 50% of the patients treated gave a tumor nodule was well over 50% ( Figure 1) . No systemic regression of uninjected tumor nodules strong local response with shrinkage of the treated tumor to less than 50% of the original size. Furthermore, it was was noticed in any of the patients treated. All patients treated had systemic progressive disease, and all patients also observed that the efficacy of tumor regression resulting from our protocol depended both on the nature subsequently succumbed to their disease. of the MHC DNA employed as well as the types and sizes of the cancers being treated.
Immediate clinical reactions Intra-lesional infiltration with MHC DNA-DC-Chol/ DOPE cationic liposomes briefly elicited mild pain in the Results lesion. All patients tolerated the injections without analgesia. There were no changes in vital signs (pulse rate Altogether, two clinical protocols were studied. and blood pressure) at 5 and 30 min after injection. No immediate local or systemic allergic reactions to the Toxicity study MHC DNA-DC-Chol/DOPE cationic liposomes were Nine patients who satisfied the entry criteria of our protoobserved. col were recruited and treated at the Cancer Centre of the Singapore General Hospital. Clinical profiles of these patients are presented in Table 1 . These patients were suffering from various cancers and exhibited progressive disease (stage IV) unresponsive to all conventional forms of therapy. During the entire protocol, patients received no other forms of treatment and all were treated as outpatients. All patients tolerated the treatment well with no acute complications, and the toxicity study was completed (see below for details of immediate and delayed clinical reactions). Of the nine patients enrolled for the treatment protocol, two patients treated with pHLA-A2- and HLA-B13-specific mRNA lasted throughout the entire study. On the other hand, no H-2K k mRNA could be detected in biopsies obtained from patients treated with the xenogeneic pH-2K k -DC-Chol/DOPE cationic liposomes even at the end of the four weekly injections (data not shown). Furthermore, when the amounts of HLA-A2-and HLA-B13-specific mRNA were compared with the amount of human growth hormone (HGH), the level of HLA-A2 mRNA was at least three-fold higher than that of the HLA-B13 mRNA after the first and second injections ( Figure 4 ).
Cervical and ovarian carcinoma trial
Ten patients with gynecological ovarian (seven patients) or cervical carcinoma (three patients) were treated in this protocol (Table 2 ). These 10 patients were HLA phenotyped and treated accordingly, based on their HLA types, with either pHLA-A2 (five patients), pHLA-B13 (three patients) or pH-2K k (two patients) plasmid DNA (Table  2) in the Department of Obstetrics and Gynaecology at the Singapore General Hospital.
Biological response
Tumor shrinkage was noted after two injections of pHLA-A2-DC-Chol/DOPE cationic liposomes in two of the three cervical carcinoma patients. Complete disappearance of the injected tumor nodule was subsequently with the maximum response seen after the fourth 786 injection. The three patients who were partial responders had tumor sizes of 3 cm or less in the greatest diameter measured before the treatment. Two of these patients received the pHLA-A2-DC-Chol/DOPE cationic liposomes, while one patient received the pH-2K k -DCChol/DOPE cationic liposomes. The ovarian cancer patient who showed less than 50% reduction in the injected nodule was given pHLA-B13-DC-Chol/DOPE cationic liposomes (Table 2 ).
All 10 patients treated in our second protocol had one distant cutaneous nodule injected in parallel with DCChol/DOPE cationic liposomes alone and none of these nodules produced a local response. Again, no systemic regression of untreated tumor nodules was noticed in any of the patients treated and all had systemic progressive disease.
All patients who received either pHLA-A2-DCChol/DOPE or pHLA-B13-DC-Chol/DOPE cationic liposomes expressed respective HLA-A2-and HLA-B13-specific mRNA after the fourth injection. In agreement with the observation made in the earlier toxicity study, no H-2K k -specific mRNA could be detected in the two ovarian carcinoma patients treated with pH-2K k -DC-Chol/DOPE cationic liposomes. 
Biochemical and hematological reactions

Analysis of serum biochemical parameters revealed no
The amounts of HLA-A2-and HLA-B13-specific PCR products derived from mRNA extracted from patient 1 ( Figure 1 white cell count and mean platelet count after the The generation of strong tumor-specific immunity by in situ gene therapy is an attractive approach for the eradication of human cancer lesions. [11] [12] [13] In this article, our results confirm and demonstrate that various recombitreatment (Table 3) . However, these changes were statistinant genes can be directly introduced and expressed in cally insignificant.
human cancer lesions in vivo via cationic liposomes. This treatment is safe and no severe toxicities were observed Immunological responses throughout our study. Following completion of the treatment plan, the generFor murine tumors, it is well known that different ation of CTL response was attempted using peripheral MHC molecules encoded by different H-2 loci vary in blood lymphocytes purified from each of the 10 patients their ability to confer tumor-specific immunity. 3, 4, 14, 15 This who participated in this study and cultured in vitro.
was explained by the observation that different murine However, due to many technical problems, such as diftumors employ different MHC molecules such as the Hficulty in maintaining viability of the patients' tumor cells 2K or H-2D molecules for the generation of H-2-restricted in vitro throughout the entire treatment period, we were CTL. 14, 16 Furthermore, it has also been observed that difonly able to perform CTL analyses using lymphocytes ferent HLA molecules are suppressed in different human purified from one of the cervical cancer patients (patient tumor cells. 17, 18 From our present studies, it is apparent 1) who showed a complete regression of her injected that allogeneic HLA and xenogeneic H-2 genes are not tumor nodule following administration of pHLA-A2-DCequivalent in their ability to generate tumor-specific Chol/DOPE cationic liposomes (Table 2 ). Following immunity in cancer patients via in situ delivery with DCstimulation in vitro with pHLA-A2-transfected autologChol/DOPE cationic liposomes. The pHLA-A2 gene was ous tumor cells, her lymphocytes showed an increase in able to generate a better biological response compared their ability to lyse autologous tumor cells in comparison with both pHLA-B13 and pH-2K k genes in the cancer with lymphocytes which were stimulated with unmodipatients treated (Tables 1 and 2 ). One NSCLC patient fied autologous tumor cells (Table 4 ). The percentages of who received pHLA-A2 DNA gave a complete local biospecific lysis against autologous tumor cells obtained follogical response, and his nodule regressed completely lowing stimulation in vitro with pHLA-A2-transfected ( Table 1 ). The effect was even more pronounced for patients with cervical and ovarian cancers who were given pHLA-A2 DNA with DC-Chol/DOPE cationic liposomes (Tables 1 and 2 ). Of the six cervical and (Tables 1 and 2 ). This included a cervical carci-
In vitro stimulator E:T Target (% killed)
noma patient who had complete regression of her injected tumor nodule following the treatment protocol tumor nodule of over 6 × 6 cm in size (Table 2) . Therefore, the size of the tumor nodule treated might also play a inclusion of such controls in our protocol meaningless.
However, it was observed, following our first toxicity would be strong enough to prevent or reduce the incidence of metastatic diseases for cervical and ovarian protocol, that in human patients no systemic immune response could be generated. Therefore, we incorporated carcinoma. the injection of DC-Chol/DOPE cationic liposomes alone into one other distant nodule in the second protocol in
Materials and methods
order to make the second study more complete.
The enhanced local biological effect of the pHLA-A2 Reagents gene could be attributed to the observation that the The 3␤(N-(N′,N′-dimethylaminoethane)carbarmoyl)-cholpHLA-A2 gene could be expressed to a higher level in esterol (DC-Chol)/dioleoylphosphatidylethanolamine the patients treated in comparison with patients receiving (DOPE) cationic liposomes were synthesized as prethe pHLA-B13 gene (Figure 4) . When the amounts of viously described. 21, 22 DOPE was purchased from Avanti HLA-A2-and HLA-B13-specific mRNA were carefully Polar Lipids (Alabaster, AL, USA). Briefly, a mixture of quantified against the HGH as an internal standard, the 1.2 mol of DC-Chol and 0.8 mol of DOPE in chloroamount of HLA-A2-specific mRNA was at least threeform was dried, vacuum desiccated, and resuspended in fold that of the corresponding HLA-B13-specific mRNA 1 ml sterile 20 mm HEPES buffer (pH 7.8). This is the after the first and second injections (Figure 4) . Although cationic liposome stock. 21, 22 the level of HLA-B13 mRNA gradually increased with the number of injections (Figure 4) , the early and abunRecombinant DNA dant expression of the exogenous allogeneic HLA gene
The HLA-A2, HLA-B13 and H-2K k cDNAs were separmight be a crucial factor in the generation of an effective ately cloned into the EcoRI site of the eukaryotic immune response against tumor cells. It might also be expression vector pCDNA-1 (Invitrogen, San Diego, CA, possible that A-locus-encoded HLA genes are more USA). The HLA-A2 and HLA-B13 cDNAs were provided immunogenic than B-locus-encoded HLA genes.
by Professor Elisabeth Weiss (Institut fü r Anthropologie Although it has previously been reported that the und Humangenetik, der Universitä t München, introduction of a 'foreign' gene coding for the hemagglutGermany); the H-2K k cDNA was cloned in our own labination antigen of influenza virus resulted in the generoratory. 23 Following cloning, the resulting expression ation of strong tumor-specific immunity against the vectors were designated as pHLA-A2, pHLA-B13 and 'wild-type' parental tumor cells, 8 our present results indipH-2K k . These plasmids were purified using a commercate that xeno-immunization with 'foreign' murine MHC cially available anion column chromatography method genes is likely to give relatively higher toxicities, lower (EndoFree Plasmid Mega Kit; Qiagen, Hilden, Germany) efficiencies of gene expression, and overall is less likely in the absence of ethidium bromide. to give a biological response in comparison to alloimmunization with HLA genes (Tables 1 and 2) .
Preparation of DNA-liposome complexes In the present phase I/II clinical studies, the obserTwo different concentrations of the pHLA-A2-, pHLAvation of a strong local biological response seen in a B13-or pH-2K k -liposome mixtures were prepared. The group of patients having relapsed stage IV systemic first DNA-DC-Chol/DOPE cationic liposome mixture metastatic disease, refractory to all available therapies was prepared by pooling four tubes each containing 20 (Table 2) , demonstrates the generation of a strong l of liposome stock and either 3 g pHLA-A2, pHLAimmune response following our gene therapy protocol in B13 or pH-2K k DNA in 0.5 ml lactated Ringer's solution situ which was previously not achievable by conventional (Ringer Lactate Infusion; Fresenius, Bad Homburg, treatments. In our earlier animal model, the introduction Germany). The second DNA-DC-Chol/DOPE cationic of allogeneic MHC genes into tumor cells generated vigliposome mixture was prepared as above except at the orous CTL reactivities against not only the exogenous end of the 20 min incubation, the contents were pooled allogeneic MHC molecules, but also generated strong (2 ml) and further diluted with an additional 2 ml of tumor-specific CTL reactivities against the 'wild-type', lactated Ringer's solution. parental tumor cells.
2 Therefore, immunization of naive mice with tumor cells transfected with allogeneic MHC Administration of DNA-liposome complexes genes will protect these immune mice against a subThe more concentrated DNA-DC-Chol/DOPE cationic sequent lethal challenge with the 'wild-type' tumor cells. 2 liposome mixture (2 ml) was injected directly into the In the present clinical studies, this observation was center of the tumor nodule, while the more diluted further substantiated by the ability of the pHLA-A2-DNA-DC-Chol/DOPE cationic liposome mixture (4 ml) transfected tumor cells to act as a potent in vitro stimuwas injected immediately outside the tumor nodule in lator in generating CTL against the autologous, unmodisuch a manner that the tumor nodule was enveloped fied, tumor cells (Table 4) . Recurrent gynecological can-('soaked') in the DNA-liposome solution. This method of cers often involve multiple sites, such as cutaneous tissue gene delivery has been observed to prolong the uptake and peripheral lymph nodes, outside the confines of the of DNA-liposome complexes by tumor cells and to pelvis. 19.20 The ability to generate potent secondary CTL increase the expression of the delivered gene in vivo (Hui, reactivities against autologous tumor cells in the patients unpublished observation). A total of four injections either who gave a biological response following treatment with of pHLA-A2-, pHLA-B13-or pH-2K k -DC-Chol/DOPE pHLA-A2-DC-Chol/DOPE cationic liposomes (Table 4) cationic liposome solutions were given per patient at would tend to support the notion that the formation of weekly intervals. tumor metastases can be reduced/prevented. It would therefore be feasible to design clinical studies to address Clinical protocols and study design The clinical studies were approved by the Singapore Minthe question of whether the immune responses generated following the introduction of allogeneic MHC genes istry of Health and the ethics committee of the Singapore General Hospital. Informed written consents were using the ARMS/PCR specific primer pair: 5′-TGGATA-GAGCAGGAGGGT-3′ and 5′-CAAGAGCGCAGGTCC obtained according to the recommendation made by the ethics committee of the Singapore General Hospital TCT-3′ (to yield a PCR product of 247 bp), 24 while to detect the HLA-B13-specific mRNA, the primer pair 5′-where the study was conducted. All patients enrolled had relapsed stage IV systemic metastatic diseases and ACCGAGAGAACCTGCGCA-3′ and 5′-GGCCGCCTCC CACTTGA-3′ (to yield a PCR product of 230 bp) was were refractory to all available therapies. All patients enrolled in our protocols were HLA typed using monoemployed. 25 To detect the H-2K k mRNA, the K-locus-specific primer pair 5′-GAACACGCAGATCGCC-3′ and 5′-clonal antibodies to determine whether they were HLA-A2 + or HLA-B13 + . To ensure allogeneicity in our protocol, TTCCAGAA GTGGGCATCTGT-3′ (to yield a PCR product of 554 bp) was employed. 23 The human growth horwe treated HLA-A2 + /HLA-B13 − patients with HLA-B13-DC-Chol/DOPE cationic liposomes; whereas HLA-A2 − mone (HGH) mRNA was detected with the primer pair 5′-GCCTTCCCAACCATTCCCTTA-3′ and 5′-TCACGGA patients were treated with HLA-A2-DC-Chol/DOPE cationic liposomes. No patients were rejected from our pro-TTTCTGTTGTGTTTC-3′. tocols based on their HLA types. For the Singaporean Criteria for local response population, it is expected that about 25% of patients will All tumor nodules injected were measurable cutaneous be HLA-A2
+ and relatively fewer patients (approximately tumor nodules in an unirradiated field accessible for 12%) will express HLA-B13. No patient should express direct injection. To determine the local cutaneous the xenogeneic H-2K k molecules. response, the largest diameter of the lesion as well as the The first toxicity study involved nine patients (Table  diameter perpendicular to the first were measured. Com-1). Initially, three patients were injected with 8 g plete local response (CLR) was recorded for patients of either pH-2K k -, pHLA-A2-or pHLA-B13-DCwhose treated nodule regressed completely; partial Chol/DOPE cationic liposome solutions. If no grade response (PLR) was recorded for patients whose treated III/IV toxicities developed, another three patients were nodule decreased by at least 50%. All patients were injected with 24 g of pH-2K k -, pHLA-A2-or pHLAreviewed each week before injection, and toxicities, if B13-DC-Chol/DOPE cationic liposome solutions. Again, any, were graded according to the NCI criteria. The last if no grade III/IV toxicities developed, the remaining evaluation was done 2 weeks after the fourth injection. three patients were given 80 g of pH-2K k -, pHLA-A2-, Full blood count and liver function tests were also monior pHLA-B13-DC-Chol/DOPE cationic liposome soltored at the beginning and at the end of each treatment. utions, representing the highest concentration of DNA injected for this toxicity study.
Immunologic analysis A second clinical study on the toxicities of employing Serum antibodies to HLA-A2, HLA-B13 and H-2K k were the pHLA-A2, pHLA-B13 and pH-2K k genes for gene evaluated by HLA-A2 + , HLA-B13 + , and H-2K k+ cell lines, therapy via DC-Chol/DOPE cationic liposomes in 10 cerrespectively. For CTL study, peripheral blood from vical and ovarian carcinoma patients with relapsed stage patients was obtained at the end of the treatment protocol IV disease previously refractory to all available therapies and lymphocytes were isolated by Ficoll-Hypaque gradiwas also carried out (Table 2) . Twenty-four micrograms ent centrifugation. CTL analyses were performed as of DNA were given per injection and a total of four injecpreviously described. 22 tions either of pHLA-A2-, pHLA-B13-or pH-2K k -DCChol/DOPE cationic liposome solutions were given per patient at weekly intervals. For this protocol, one tumor
